A US court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.
Mission Bio has launched a tool it claims will help save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster.
Human tissue-focused products and services firm Reprocell Europe has opened headquarters in Glasgow, Scotland, which it says will boost business and create jobs.
Absorption Systems has announced a technology licensing agreement with Pfizer Inc., in which the pharma company will use the preclinical CRO’s cell lines to test potential drug candidates.
Metrion Biosciences has been awarded a grant to develop CiPA-compliant stem cells and screening technologies by Eurostars, a European Union (EU) programme.
Contractor Trenzyme GmbH has licensed a CHO cell line-based expression system from Swiss firm Celonic AG in a deal designed to expand its service offering.
CMO ProBioGen says its GlymaxX ADCC antibody enhancement technology can be adapted to any biomanufacturing cell line and will attract both Big and Small Pharma.
Protalix Biotherapeutics is attempting to use its US FDA-approved Gaucher's disease treatment as a proof of concept and springboard for its plant-based cell manufacturing technology.
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
A spectrum of systems could eventually replace animal testing and provide a more ethical and economical route through preclinical, according to Kate Darley, business development manager at Kirkstall.
At TIDES 2009 RXi Pharmaceuticals presented preclinical data on its RNA technologies, including research into sdRNA that is delivered without a vehicle and undergoes spontaneous cellular uptake.
Crucell and DSM Biologics have added fellow Dutch firm Bioceros to the PER.C6 vendor network to provide manufacturing and support capacity in line with increased demand for the cell line.
Ion channel expert ChanTest is expanding its range of ion channel services and cell lines that help identify promising target compounds and those that could cause harmful side effects.
Medgenics' Biopump could be the solution to the issues surrounding
protein therapy and is set to take on the $51bn US
biopharmaceutical market after raising £3.28m ($6.76m) in funding
in its Initial Public Offering.
Tecan and GE Healthcare Life Sciences division are collaborating to
simplify high throughput (HT) protein purification by increasing
the speed and reliability of expression screening programmes.
UK researchers have developed a plastic cell scaffold that enables
cells to be grown in realistic 3D structures and promises to enable
better cell based drug screening results.
Sigma-Aldrich has launched a new technology that promises to
dramatically simplify and speed-up high-throughput (HT) RNAi
screening of the human kinome.
Nikon have launched a new 'hands off' system that combines an
incubator and inverted microscope to allow automated live-cell
culture studies and time-lapse imaging in a controlled environment.
Researchers have developed a biochip that could prove crucial in
future drug development. The technology measures electrical
activities of cells and can obtain 60 times more data in one
reading than is possible with current technology.
Researchers have isolated a protein that appears to encourage cell
movement when tumours begin to spread to other parts of the body
opening up the way for a drug that could block the beginning of
this dangerous process, or stop it...
A new ethics report has raised concerns about using animal-human
embryonic hybrids in drug testing in which the creation of these
chimeras are creating exciting avenues of research as well as
controversy.
Centocor has enlisted Cardinal Health to use its rapid cell line
development technology to engineer cell lines expressing Centocor's
monoclonal antibodies, and speed up the development of new
biopharmaceuticals.
Chromos has announced an expansion to an existing Pfizer
collaboration, which builds on research focusing on genetic
engineering of production cell lines with multiple genes to improve
bioreactor performance and reduce monoclonal...
Researchers have identified two proteins involved in the process
that controls plant growth, which may help explain why human cells
reject chemotherapy drugs and could form a basis for new oncology
drugs.
Researchers have combined nanotechnology with biochemistry to
create synthetic membranes that, for the first time, enable direct
control of signalling activity in living T cells from the immune
system, which could lead to better development...
Innovata of the UK has sold off its gene expression technology UCOE
to Celliance Corp, a wholly owned subsidiary of Serologicals, for
an undisclosed fee.
The drug resistance encountered by scientists when treating cancer
cells has been the subject of research by German scientists who
believe they have identified a cellular protein, which mediates a
death signal.
Chromos Molecular Systems won another customer for its cell line
engineering technology yesterday, when world number one drugmaker
Pfizer took out a license for its ACE system, reports Phil
Taylor.
Canada's Chromos Molecular Systems and AppTec Laboratory Services
have teamed up to provide the biopharmaceutical industry with a
broader range of cell line engineering and contract manufacturing
services.
Vitra Bioscience has introduced a new nuclear translocation
application, a new method enabling the measurement of
cytoplasm-to-nucleus translocation, a critical indicator of
cellular response to various drug treatments.
Dharmacon has launched a range of small interfering RNA (siRNA)
transfection reagents designed specifically to enhance transfection
efficiency, a crucial procedure in initial drug target
identification to late-stage therapeutic development.
In-Pharmatechnologist.com recently reported on the opening of a new
biomanufacturing facility and laboratory by France's Lemnagene, a
new company specialising in the production of recombinant proteins
in duckweed. But why is...
The first commercial products from chloroplast transformation
technology (CTT) looks a distinct possibility after Chlorogen
signed a joint development and supply agreement with Sigma-Aldrich
to produce four specific proteins in tobacco...
A new method to improve the accuracy and speed of protein
visualization has been developed. The technique, which uses a novel
set of biosensor dyes, promises to dramatically increase the
accuracy and speed of the technique, used in...
Canada's Chromos Molecular Systems has entered into a collaborative
agreement with Centocor, a wholly-owned subsidiary of Johnson &
Johnson, to develop cell lines for the manufacture of biological
drugs.
Germany's Icon Genetics and Israeli firm Protalix are to
collaborate on a way of hiking protein expression in plant cells to
improve their use a production vehicle for recombinant proteins.
Contract research manufacturer Diosynth has forged a joint venture
with a Swiss firm for a technology that could dramatically reduce
the time and cost of developing new cell lines for manufacturing
proteins, writes Phil Taylor.